✦ LIBER ✦

Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML)

✍ Scribed by A. Ganser; G. Heil; G. Seipelt; W. Hofmann; J. T. Fischer; W. Langer; W. Brockhaus; K. Kolbe; T. H. Ittel; N. Brack; H. G. Fuhr; P. Knuth; K. Höffken; L. Bergmann; D. Hoelzer

Publisher: Springer
Year: 2000
Tongue: English
Weight: 104 KB
Volume: 79
Category: Article
ISSN: 0939-5555
DOI: 10.1007/s002770050005

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Intensive chemotherapy with idarubicin,

Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia

✍ W. K. Hofmann; G. Heil; C. Zander; S. Wiebe; O. G. Ottmann; L. Bergmann; K. Hoef 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 109 KB

Results of a multicenter phase II trial

Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib

✍ Florian Heidel; Jorge Cortes; Frank G. Rücker; Walter Aulitzky; Laurie Letvak; T 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 154 KB 👁 2 views